AMAL, Sweden—Hexpol TPE has announced a $6.6 million investment at its production plant in Amal to support "increasing demand and evolving market requirements."
In a Sept. 16 statement, the Swedish thermoplastic elastomers compounder said construction work has started on a new hall, which will be dedicated to medical grades.
Set for completion by fall of 2022, the new building will meet strict standards in terms of "cleanliness, traceability, and reproducibility controls," Hexpol TPE said.
The facility will house a new twin-screw compounding line with gravimetric feeders and advanced monitoring systems adopted for medical production.
"We're ... ensuring we maintain the very high standards, processes, and operations required for our customers while expanding our production capacity," said Ralph Wolkener, president Hexpol Compounding, Europe/Asia.
With optimized internal logistics and increased automation and robotics, the project lays the foundation for future development, added Carsten Rüter, president of Hexpol Compounding global purchasing/technology.
Hexpol TPE produced its first medical compounds in the 1990s and launched the Mediprene range of TPEs for medical applications in 2004.
The company was the first TPE compounder in Europe to gain the ISO 13485 accreditation in 2007.
"This investment confirms Hexpol's ongoing commitment to this important product area," said Georg Brunstam, Hexpol Group president and CEO.
"Hexpol invests to ensure we deliver the know-how, performance and reliability our customers deserve."